Low-dose cytarabine (ara-C) is not generally perceived as a good therapy for AML, particularly in the US, whereas hypomethylating agents are a more standard approach. However, is the potential of cytarabine as part of combination regimens being overlooked in clinical trials? Here, Jorge Cortes, MD, of the MD Anderson Cancer Center, Houston, TX, discusses the issues surrounding this, including whether we can predict which patients could benefit from combinations containing cytarabine. This video was recorded at the 1st International Workshop on Acute Leukemias (iwAL), held in St. Pete Beach, FL.
Is low-dose cytarabine being overlooked in combination therapies for elderly AML?
